Search results for "ANALOGS"

showing 10 items of 53 documents

Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines

2005

Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was replaced either by a five-membered heterocyclic (isoxazoline or isoxazole) or by a six-membered ring (pyridine or benzene). The new compounds have been evaluated for their effects on tubulin assembly and for cytotoxic and apoptotic activities. Five compounds (18b, 20a, 21a, 34b, and 35b) demonstrated an attractive profile of cytotoxicity (IC501 microM) and apoptosis-inducing activity but poor antitubulin activity. The isoxazoline derivatives 18b, 20a, and 21a, demonstrated potent apoptotic activity different from that of natural CA-4. Their ability to block most cells in the G2 phase suggests…

Models MolecularA-4 ANALOGSDouble bondHL60StereochemistryPyridinesTUBULINApoptosisANTINEOPLASTIC AGENTSchemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryStilbenesBenzene DerivativesHumansIsoxazoleBIOLOGICAL EVALUATIONCytotoxicitychemistry.chemical_classificationCombretastatinbiologyCOLCHICINEDEATHIsoxazolesDrug Resistance MultipleTubulinANTIMITOTIC ANTITUMOR AGENTSMULTIDRUGchemistryApoptosisCell cultureDrug Resistance NeoplasmDISCOVERYbiology.proteinMolecular MedicineDrug Screening Assays AntitumorSOLID TUMOR-THERAPY
researchProduct

1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase.

2021

A new series of topsentin analogs, in which the central imidazole ring of the natural lead was replaced by a 1,2,4- oxadiazole moiety, was efficiently synthesized. All derivatives were pre-screened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. The five most potent compounds were further investigated in various pancreatic ductal adenocarcinoma (PDAC) cell lines, including SUIT-2, Capan-1, and Panc-1 cells, eliciting EC50 values in the micromolar and sub-micromolar range, associated with significant reduction of cell migration. These remarkable results might be explained by the effects of these new topsentin analogues on epithelial-to-mesenchy…

Models MolecularIndoles124-oxadiazole topsentin analogs; GSK3β kinase; inhibition of migration; PDAC antiproliferative activity; proapoptotic activityApoptosisDrug Screening Assays01 natural sciencesBiochemistrychemistry.chemical_compound124-oxadiazole topsentin analogs; GSK3β kinase; PDAC antiproliferative activity; inhibition of migration; proapoptotic activity; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Glycogen Synthase Kinase 3 beta; Humans; Imidazoles; Indoles; Models Molecular; Molecular Structure; Oxadiazoles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells CulturedModelsAnnexinDrug DiscoveryTumor Cells CulturedGSK3β kinaseGeneral Pharmacology Toxicology and Pharmaceutics4-oxadiazole topsentin analogsOxadiazolesCulturedMolecular StructureChemistryKinaseImidazolesCell migrationTumor Cellsinhibition of migrationMolecular MedicineDrugIntracellularPDAC antiproliferative activityproapoptotic activityCell Survival12Antineoplastic AgentsDose-Response RelationshipStructure-Activity RelationshipPancreatic cancermedicineHumansPropidium iodideProtein Kinase InhibitorsCell ProliferationPharmacologyGlycogen Synthase Kinase 3 betaDose-Response Relationship Drug010405 organic chemistryOrganic ChemistryMolecularAntitumormedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaMolecular biology0104 chemical sciencesPancreatic Neoplasms010404 medicinal & biomolecular chemistryApoptosisCell cultureDrug Screening Assays Antitumor124-oxadiazole topsentin analogChemMedChem
researchProduct

Phosphonic Acid Analogs of Fluorophenylalanines as Inhibitors of Human and Porcine Aminopeptidases N: Validation of the Importance of the Substitutio…

2020

International audience; A library of phosphonic acid analogs of phenylalanine substituted with fluorine, chlorine and trifluoromethyl moieties on the aromatic ring was synthesized and evaluated for inhibitory activity against human (hAPN) and porcine (pAPN) aminopeptidases. Fluorogenic screening indicated that these analogs are micromolar or submicromolar inhibitors, both enzymes being more active against hAPN. In order to better understand the mode of the action of the most active compounds, molecular modeling was used. It confirmed that aminophosphonic portion of the enzyme is bound nearly identically in the case of all the studied compounds, whereas the difference in activity results fro…

Models MolecularMolecular modelPhosphorous AcidsSwineStereochemistrylcsh:QR1-502chemistry.chemical_elementPhenylalanine[CHIM.THER]Chemical Sciences/Medicinal ChemistryCD13 AntigensRing (chemistry)Biochemistrylcsh:MicrobiologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinefluorineinhibitorsChlorineSide chainAnimalsHumansMolecular BiologyEnzyme Assays030304 developmental biologyphosphonic acid analogschemistry.chemical_classification0303 health sciencesTrifluoromethyl[CHIM.ORGA]Chemical Sciences/Organic chemistrymolecular modelingReproducibility of ResultsStereoisomerismMolecular Docking SimulationEnzymechemistry030220 oncology & carcinogenesishuman and porcine aminopeptidaseEnantiomerMolecules
researchProduct

A computational study to explore the molecular mechanisms behind the antiproliferative activity of Nortopsentin derivatives

2018

Nortopsentin analogs antitumor activity computational studies
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Cuticular hydrocarbon profiles in Blattella germanica: effects of halofenozide, boric acid and benfuracarb

2006

1379-1176 (Print) Journal Article; In order to complete previous studies conducted on Blattella germanica, three insecticides from different groups were evaluated: boric acid, an inorganic compound, benfuracarb, a carbamate, and halofenozide, a non-steroidal ecdysone agonist. Boric acid (8.20%, LD50) and benfuracarb (2%, LD50) were incorporated into the diet and orally administrated to newly emerged adults of both sexes, while halofenozide (0.33%, LD50) was applied topically. Hydrocarbons extracts was made on bidistilled pentane from control and treated series sampled 6 days following treatment. Extracts was analyzed by gas chromatography. Data showed that cuticular profiles of control and …

OralMaleChromatographyHydrazines/*toxicityTime Factorsintegumentary systembeta-Alanine/*analogs & derivatives/toxicityHydrocarbons/*analysisBenzofurans/*toxicityBenzoic Acids/*toxicityLethal Dose 50TopicalInsecticides/*toxicityBoric Acids/*toxicityGasAdministrationAnimalsFemaleBlattellidae/chemistry/drug effects/growth & development
researchProduct

Efficacy of levetiracetam in the treatment of drug-resistant Rett Syndrome.

2010

Rett syndrome (RTT) is a progressive neurological disorder characterized by a wide spectrum of phenotypes. Epilepsy is reported to occur in 50–90% of patients with RTT; some develop medically refractory epilepsy. The aim of this study is to investigate the efficacy of levetiracetam (LEV) in drug-resistant patients with RTT. This prospective, pragmatic, open-label study consisted of an 8-week baseline period and a 6-month evaluation period. Efficacy variable was the mean frequency of monthly seizures before, and after 3 and 6 months of treatment with LEV. Eight female patients, aged 7.5–19 years (M12.8 ± 5) entered the study. Mean age at epilepsy onset was 25.8 ± 14.1 months. All patients sh…

Pediatricsmedicine.medical_specialtyLevetiracetamAdolescentMethyl-CpG-Binding Protein 2medicine.medical_treatmentRett syndromeNeurological disorderDrug Administration ScheduleCentral nervous system diseasedrug therapy/geneticsYoung AdultEpilepsyanalogs /&/ derivatives/therapeutic useSeizuresConvulsionmedicineRett SyndromeHumansgeneticsEEGProspective StudiesMyoclonic seizuresChildProspective cohort studyPsychiatryDrug-resistanceAnalysis of Variancebusiness.industryPatient SelectionFocal seizureElectroencephalographymedicine.diseaseAdolescent Analysis of Variance Anticonvulsants; therapeutic use Child Drug Administration Schedule Electroencephalography Female Humans Methyl-CpG-Binding Protein 2; genetics Patient Selection Piracetam; analogs /&/ derivatives/therapeutic use Prospective Studies Quality of Life Rett Syndrome; drug therapy/genetics Seizures; drug therapy/genetics Treatment Outcome Young AdultPiracetamSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeAnticonvulsantNeurologytherapeutic useQuality of LifeAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessmedicine.drug
researchProduct

Reversion of 7-methylguanosine 5′-phosphate inhibition of mRNA translation by polysomal and soluble factors isolated from Saccharomyces cerevisiae

1987

Abstract Protein fractions that overcome m7GMP inhibition of mRNA translation have been purified from the yeast S. cerevisiae . An active fraction isolated from polysomes contains two polypeptides of 220- and 190-kDa. The active fraction isolated from postribosomal supernatant contains a major polypeptide of 28-kDa and other species of 32-, 24-, 22- and 21-kDa, and sediments in sucrose gradients as a high molecular weight complex of about 200000. This fraction restored yeast mRNA translation in reticulocyte lysates under conditions of yeast and globin mRNA competition; however, this effect was not observed with the 220- and 190-kDa polypeptides from polysomes. Nevertheless, translation of y…

RNA CapsSucroseSaccharomyces cerevisiaeBiophysicsReversionSaccharomyces cerevisiaeRNA Cap AnalogsBiochemistryFungal Proteinschemistry.chemical_compoundReticulocytePolysomemedicineRNA MessengerMolecular BiologyMessenger RNAbiologyTranslation (biology)Cell Biologybiology.organism_classificationMolecular biologyYeastKineticsmedicine.anatomical_structurechemistryBiochemistryPolyribosomesProtein BiosynthesisBiochemical and Biophysical Research Communications
researchProduct